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Previous studies have described patients with
upper and lower airway symptoms induced by
chemicals and scents (Johansson et al. 2006;
Millqvist 2000; Millqvist et al. 1998;
Ternesten-Hasseus et al. 2002a, 2002b).
Inducing factors can include perfume, ﬂowers,
cleaning agents, car-exhaust fumes, and ciga-
rette smoke. Steroids, β2-agonists, and other
pharmacologic treatment for asthma or allergy
have weak effects or none at all. Common
symptoms are heavy breathing, difﬁculty get-
ting air, cough, hoarseness, phlegm, nasal
blockage, rhinorrhea, and eye irritation. The
symptoms are often misinterpreted as asthma
and/or allergy. Sensory hyperreactivity (SHR)
is one suggested explanation for these airway
symptoms induced by chemicals and scents
(Johansson et al. 2002; Millqvist et al. 1998).
The diagnostic criteria for the proposed diag-
nosis of SHR include self-reported sensitivity
to chemicals and scents and a positive reaction
to a capsaicin inhalation test, with the cut-off
values described by Johansson et al. (2002).
The prevalence of SHR has been estimated at
6.3% (Johansson et al. 2006).
There is a strong resemblance between
SHR and multiple chemical sensitivity
(MCS), but the diagnosis of SHR implies that
just one organ is affected—the airways—
whereas in MCS, symptoms from multiple
organs are involved. However, some patients
with SHR also complain of more general
symptoms, such as sweating, dizziness,
headache, and fatigue, bordering on a diagno-
sis of MCS (Ternesten-Hasseus et al. 2002a).
MCS is also known as “the 20th century dis-
ease,” “chemically acquired immunodeﬁciency
syndrome,” “total allergy syndrome,” and
“idiopathic environmental intolerances”
(American Academy of Allergy, Asthma and
Immunology Board of Directors 1999;
Graveling et al. 1999). MCS is associated with
a generalized sensitivity to low doses of chemi-
cals (normally regarded as nontoxic) in the
environment, with symptoms from various
organs (including the airways) and often non-
speciﬁc symptoms such as fatigue and cogni-
tive difficulties. Cullen (1987) defined the
condition according to its major features. The
definition of MCS may cover a number of
conditions in patients with various symptoms
and undiagnosed disorders. 
Capsaicin, which stimulates the unmyeli-
nated C-ﬁbers of the sensory nervous system,
has long been used to assess cough sensitivity
related to airway sensory nerves (Fuller et al.
1985; Karlsson et al. 1988; Midgren et al.
1992; Morice and Geppetti 2004). Inhalation
of capsaicin induces cough in a safe and dose-
dependent manner, and it has good short-
and long-term repeatability (Dicpinigaitis
2003; Dicpinigaitis and Alva 2005; Millqvist
et al. 1998; Ternesten-Hasseus et al. 2006).
However, the long-term repeatability of cap-
saicin cough challenge has only been studied in
healthy subjects (Dicpinigaitis 2003). Patients
with airway symptoms induced by chemicals
and scents react more strongly than healthy
controls and asthmatic patients to inhaled cap-
saicin (Johansson et al. 2002; Millqvist et al.
1998; Ternesten-Hasseus et al. 2002b), sup-
porting the hypothesis that the explanation
seems to be an overreaction of the sensory ner-
vous system of the airways followed by a
hyperreactivity to chemicals and scents—a sen-
sory hyperreactivity. Increased cough sensitiv-
ity to inhaled capsaicin has also been found in
MCS patients with airway symptoms (Nogami
et al. 2004; Ternesten-Hasseus et al. 2002a).
Previously, significantly increased levels of
nerve growth factor in nasal lavage after cap-
saicin inhalation have been found in patients
with SHR, suggesting a neurochemical imbal-
ance of the respiratory system in these patients
(Millqvist et al. 2005). 
Health-related quality of life (HRQL) is a
measure of how diseases and symptoms affect
health, well being, and the ability to function
in daily life. The Nottingham Health Proﬁle
(NHP) questionnaire was developed at
Nottingham University (UK) for measuring
subjective health status and has been used in
several studies of various chronic illnesses and
conditions (Löth et al. 1998; Ringsberg et al.
1990; Tsukino et al. 1996; Wiklund et al.
1991). Bilingual health care personnel have
translated the NHP from English to Swedish,
with the aim of expressing how patients expe-
rience the effects of illness, as stated in their
own words. MCS has been found to nega-
tively affect HRQL (Black et al. 1999), but
there are few studies describing HRQL in
patients with SHR (Millqvist et al. 2000).
The aims of the present study were to
a) evaluate the duration of symptoms and to
measure HRQL in patients with airway
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OBJECTIVE: It is common in asthma and allergy clinics to see patients presenting with upper and
lower airway symptoms that are induced by chemicals and scents and not explained by allergic or
asthmatic reactions. Previous studies have shown that these patients often have increased cough sen-
sitivity to inhaled capsaicin; such sensitivity is known to reﬂect the airway sensory reactivity. The
aim of this study was to evaluate the duration of symptoms induced by chemicals and scents and to
measure health-related quality of life (HRQL) in patients with chemically induced airway symptoms.
We also wished to determine and compare repeatability of the cough response to capsaicin inhala-
tion, and to evaluate the patients’ airway sensory reactivity in a long-term perspective. 
PARTICIPANTS: Seventeen patients with a history of at least 12 months of airway symptoms induced
by chemicals and scents were followed over 5 years with repeated questionnaires, measurements of
HRQL, and capsaicin inhalation tests. 
RESULTS: The symptoms persisted and did not change signiﬁcantly over time, and the patients had
a reduced HRQL that did not change during the 5-year period. The capsaicin sensitivity was
increased at the start of the study, the cough sensitivity was long-lasting, and the repeatability of
the capsaicin inhalation test was considered to be good in a long-term perspective. 
CONCLUSIONS: Upper and lower airway symptoms induced by chemicals and scents represent an
entity of chronic diseases, different from asthma or chronic obstructive pulmonary disease, with
persistent symptoms, a reduced HRQL, and unchanged sensory hyperreactivity. 
KEY WORDS: asthma, capsaicin, cough, environment, health-related quality of life, multiple
chemical sensitivity, sensory hyperreactivity. Environ Health Perspect 115:425–429 (2007).
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Research | Environmental Medicinesymptoms induced by chemicals and scents;
b) determine and compare repeatability of the
cough response to capsaicin inhalation; and
c) evaluate the patients’ sensory reactivity in a
long-term perspective. 
Materials and Methods 
Patients. The study group included 17 patients
(13 women and 4 men; median age of
48 years) who were consecutively selected over
a period of about 9 months, when they were
referred to our outpatient asthma and allergy
clinic because of symptoms suggestive of
asthma or allergies accompanied by treatment
failure. They were screened using a question-
naire on airway symptoms and symptoms in
response to chemicals and scents. The patients
had at least a 1 year (median 9 years) history
of upper and lower airway symptoms induced
by chemicals and scents. Within the last
3 years, all patients had had a skin prick test
(SPT) with a standard panel of 10 allergen
sources common to Sweden. The SPT was
negative for all of the patients except for two
who had a minor positive reaction to mug-
wort, which was regarded as being without
clinical importance. The methacholine test,
administered according to the method
described by Lowhagen (1984), was negative
for all patients. None of the patients demon-
strated spirometric reversibility or variability in
pulmonary function. Ten of the patients had
never smoked, six had ceased smoking
> 2 years before the study began, and one had
ceased smoking 2 months previously. All par-
ticipants except one were tested in a standard-
ized way with the 1-butanol threshold test and
the Scandinavian Odor-Identification Test
(SOIT) (Cain et al. 1988; Nordin et al. 1998).
All had a normal sense of smell according to
the SOIT, although three had hyposmia (a
reduced ability to smell and to detect odors)
according to the 1-butanol test. Demographic
data of the patients are presented in Table 1. 
Informed consent was obtained from all
patients. The study was approved by the
Regional Ethical Review Board of Göteborg,
Sweden. 
Study design. The patients were followed
over a period of approximately 5 years. The
patients saw their ordinary physician during
the follow-up time, and we did not interfere
in their treatment. During the first year,
patients visited the clinic four times for a cap-
saicin inhalation test. They then visited the
clinic approximately once a year during the
following 4 years. At each study visit, the
patients underwent a capsaicin inhalation test
(eight capsaicin tests in total). Before the ﬁrst
appointment, and once per year thereafter,
the patients answered a local questionnaire
and their HRQL was evaluated (six times in
total). All of the questionnaires were handed
out to the patients and answered before the
capsaicin inhalation test. If a patient was
unable to come to the clinic, the question-
naires were sent by mail, completed at home,
and mailed back. 
Questionnaires. At the beginning of the
study, the patients answered a local question-
naire about symptoms and triggering factors
for symptoms. They were asked to score symp-
toms that they had experienced over the previ-
ous year on a scale of 0–3 (0 = no symptoms;
1 = mild symptoms; 2 = moderate symptoms;
and 3 = severe symptoms). Fourteen symp-
toms were analyzed: heavy breathing, diffi-
culty getting air, chest weight, cough, phlegm,
throat irritation, hoarseness, nasal blockage,
rhinorrhea, eye irritation, sweating, headache,
dizziness, and fatigue. To allow test–retest
evaluation of the symptom score questionnaire,
the patients completed this questionnaire twice
at the beginning of the study. The patients
were also asked about their working capacity
and the medication they used at the start of the
study and then once each year. 
Health-related quality of life. HRQL was
assessed using the NHP questionnaire, a
generic, self-administered instrument for meas-
uring various aspects of HRQL (Hunt and
McEwen 1980). The questionnaire has been
shown to have both high validity and high
reliability (Hunt et al. 1981, 1984; Wiklund
et al. 1988). It consists of two parts. Part I
contains 38 items covering six aspects of
HRQL, concerning the domains of physical
mobility, pain, energy, sleep, social isolation,
and emotional reactions. The response alterna-
tives for each item are “yes” and “no,” depend-
ing on whether that item ﬁts the individual’s
current situation. The possible score for each
dimension ranges from zero (no problems at
all) to 100 (presence of all problems within
the area). The weighting procedure is based on
Thurstone’s “paired comparison” method
(McKenna et al. 1981). Part II of the NHP
contains seven questions, again with yes/no
alternatives, concerning the impact of health
problems on the individual’s social function-
ing in terms of paid employment, housework,
social life, family life, sex life, hobbies, and
holidays. For part II, the proportions of posi-
tive answers to each of the seven questions are
calculated separately and compared with the
reference values. The patients were asked to
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Table 1. Demographic data for 17 patients with airway symptoms induced by chemicals and scents.
Patient  Age Duration of  Baseline FEV1
no. Sex (years) symptoms (years) (percent predicted) Profession
1 F 45 3 95 Secretary/unemployed
2 M 42 2 87 Clerk
3 F 60 21 91 Disability pension
4 F 52 15 77 Nurse/periodically sick-listed
5 F 58 10 109 Teacher/periodically sick-listed
6 M 56 10 83 Clerk
7 M 48 8 88 Priest/periodically sick-listed
8 F 52 3 120 Nurse/periodically sick-listed
9 F 48 11 109 Occupational therapist’s assistant
10 F 37 4 95 Clerk
11 F 30 10 121 Statistician
12 F 31 15 131 Artist/unemployed
13 F 47 2 112 Postman/periodically sick-listed
14 M 61 5 91 Disability pension
15 F 53 1 106 Clerk
16 F 38 25 96 Salesman
17 F 27 2 78 Engineer/periodically sick-listed
Abbreviations: F, female; FEV1, forced expiratory volume in 1 sec; M, male.
Table 2. Number of patients reporting trigger factors, symptoms, and medication at the ﬁrst and last visits
in the study.
No. of  Symptoms  No. of  No. of patients
Trigger factors patients reported patients Medication First visit  Last visit
Flower scents 14 Heavy breathing 15 Inhalation steroids 1 1
Car exhaust fumes 13 Difﬁculty getting air 11 Nasal steroids 6 1
Perfume 16 Chest weight  14 Oral steroids 2 0
Cigarette smoke 16 Cough 17 Antihistamines 2 3
Colored paints 16 Phlegm 12 β2-Agonists 6 2
Exercise 15 Throat irritation 12 Antidepressant medication 2 2







Fatigue 13answer the questions according to their actual
current condition. 
Reference values for NHP. We used norm
and reference values distributed by age and
sex for parts I and II of the NHP. These val-
ues are based on data from larger populations
that are currently used in family practice
(Hunt and Wiklund 1987). 
Capsaicin inhalation. We prepared a stock
solution of capsaicin [Sigma-Aldrich Sweden
AB, Stockholm, Sweden; 1 mmol/L in ethanol
(99.5%)]. We then diluted the stock solution
with 0.9% saline, containing 1% ethanol by
volume, to prepare aqueous provocation solu-
tions of 0.4, 2, and 10 µmol/L. The provoca-
tion solutions were prepared regularly and
stored frozen. A capsaicin aqueous solution of
100 µmol/L retains total stability after
3 months of storage in a freezer (Ternesten-
Hasseus et al. 2002b). 
Capsaicin was nebulized (Pari Boy 36,
type 37.0130; Paulritzau Pari-Werk GmbH,
Starnberg, Germany) and inhaled through a
mouthpiece (Pari Inhalierboy, no. 36.75) by
tidal volume breathing; a nose clip was not
used. Saline (1 mL) and the three increasing
concentrations of capsaicin (0.4, 2, and
10 µmol/L) in a 1-mL solution were inhaled
to completion, or for a maximum of 6 min, in
order to induce coughing; this was followed
by a 4-min rest period. The total number of
evoked coughs was counted for 10 min from
the onset of each inhaled capsaicin concentra-
tion. Cough registration was performed by the
same counter using a tape recorder. The total
duration of each capsaicin inhalation test was
approximately 45 min. On the ﬁrst three occa-
sions, no limit was set on the number of
coughs. In the following tests, however, out of
consideration for the patients, provocation was
stopped if one dose of capsaicin provoked
> 70 coughs. The forced expiratory volume in
1 sec (FEV1) was measured using a calibrated
spirometer (Vitalograph, Buckingham, UK)
before and after the inhalation test, and the
highest of three values was recorded. 
Capsaicin inhalation was not performed
in patients who had experienced respiratory
infections within 1 month before scheduled
testing. All medication was withheld for at
least 4 hr, and antihistamines were withheld
for at least 5 days before the inhalation tests. 
Statistical analysis. We used the Wilcoxon
signed-rank test for paired data and the
Mann-Whitney U-test for nonpaired data.
The test–retest reliability of the symptom
score questionnaire was determined using
Spearman’s rank correlation coefficient. For
part I of the NHP, we used Friedman’s test to
compare repeated measurements. Fisher’s
exact test was used in part II for nonpaired
data, and Cochran’s Q-test was used in part II
for repeated measurements. 
The repeatability of the capsaicin inhala-
tion test was determined using the method of
Bland and Altman (1986). In this method,
repeatability is analyzed by taking repeated
measurements on a series of subjects. The
result is examined using a simple plot showing
the results of one measurement against those
of the other measurement for each subject,
and a plot of the difference between the mea-
surements against their mean. The coefﬁcient
of reproducibility is calculated as 2 standard
deviations (SDs) from the mean of the differ-
ence in coughing.
A probability (p) value < 0.05 was consid-
ered statistically signiﬁcant. 
Results 
Each of the 17 subjects visited the clinic four
times during the first year. Three patients
declined to perform the capsaicin provocation
in year 3, and four patients declined in years 4
and 5. The reasons for drop out were recurrent
airway infections (subjects 1, 8, and 13), mov-
ing to another city (subject 7), fear of experi-
encing prolonged airway symptoms due to the
provocation (subject 12), and pregnancy or
expected pregnancy (subjects 11 and 17). 
The median value of FEV1 was 96% of
that predicted before the first capsaicin
inhalation test, and no significant difference
was found after the capsaicin provocations.
During the 5-year follow-up, we found no sig-
niﬁcant changes in the median values of FEV1
compared with the initial baseline values.
Questionnaires. Table 2 presents patient
data about medications used at the ﬁrst and the
last visit of the study, reported symptoms at
the ﬁrst appointment in the study, and factors
triggering these symptoms. During the 5-year
follow-up, 3 patients were granted a disability
pension, whereas 9 patients had problems with
their working capacity because of their sensitiv-
ity to chemical agents; 6 of these patients were
periodically on sick leave because of their
symptoms, alone or together with other condi-
tions (muscular problems in 3 patients). There
were some individual variations in the symp-
tom scores, but in the group as a whole, the
patients reported persistent symptoms without
statistically signiﬁcant changes between the ﬁrst
and the last visit during the study (Table 3). 
The test–retest reliability of the symptom
score questionnaire was high (rs = 0.77;
p < 0.01) indicating good reliability for the
questionnaire. 
Health-related quality of life. In the
primary evaluation for part I of the NHP,
patients had a signiﬁcantly higher (p < 0.01)
score for social isolation than the reference
group. There were no statistically significant
differences compared with the reference group
in the other ﬁve dimensions (physical mobility,
pain, energy, sleep, and emotional reactions).
Part II of the NHP is presented in Figure 1 as a
percentage of positive responses. The patients
demonstrated signiﬁcantly more problems than
the reference group for ﬁve of the seven ques-
tions: paid employment (p < 0.05), housework
(p < 0.05), social life (p < 0.01), hobbies
(p < 0.01), and holidays (p < 0.05). Over the
4-year period the patients demonstrated no
significant changes in any parts of the NHP
compared with their initial evaluation. 
Capsaicin inhalation. We counted the
number of coughs by listening to the tape
Chemically induced airway symptoms 
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Table 3. Severity (mean ± SD) of 14 symptoms in
17 patients in the first and last visits of the study,
based on a score of 0–3.
Symptom First visit Last visit
Heavy breathing 1.35 ± 1.11 1.12 ± 0.78
Difﬁculty getting air 0.76 ± 0.90 0.59 ± 0.79
Chest weight 1.17 ± 1.18 0.82 ± 1.01
Cough 1.53 ± 1.12 1.70 ± 0.98
Phlegm 1.18 ± 1.07 1.29 ± 1.07
Throat irritation 1.09 ± 0.83 1.09 ± 0.98
Hoarseness 1.00 ± 1.27 0.70 ± 1.04
Nasal blockage 1.18 ± 1.33 1.23 ± 1.15
Rhinorrhea 1.24 ± 1.03 0.88 ± 0.92
Eye irritation 1.24 ± 1.09 0.88 ± 0.99
Sweating 0.88 ± 0.99 0.88 ± 0.99
Headache 1.18 ± 1.07 1.47 ± 1.23
Dizziness 0.29 ± 0.77 0.47 ± 0.72
Fatigue 1.64 ± 1.17 1.53 ± 1.28
Figure 1. Percentage of positive responses reﬂecting problems in daily activity at the ﬁrst appointment in
year 1 in part II of the NHP for 17 patients and reference values. NS, not signiﬁcant. 








































NSrecordings. The patients coughed dose-
dependently during the capsaicin provoca-
tions (Figure 2). Of the 17 patients, 15 had
increased capsaicin cough sensitivity and
reached the threshold set for the diagnosis of
SHR according to Johansson et al. (2002). The
inhalation was stopped for approximately
8 patients during each capsaicin inhalation test
because they responded to one dose with
> 70 coughs. Because there was no cough limit
for the initial three provocations in the first
year of the study, these results were not com-
pared with the others. On each test occasion,
many patients reached the cough limit at the
highest dose of inhaled capsaicin (10 µmol/L);
therefore, only results from the doses of 0.4
and 2 µmol/L are presented. We observed no
signiﬁcant differences between the numbers of
coughs during the fourth provocation of the
ﬁrst year and the provocations of the second
and third years. There was a significant
decrease in the number of coughs between the
fourth provocation of the first year and the
provocations of the fourth and fifth years
(p < 0.05). 
We calculated repeatability using a cap-
saicin concentration of 2 µmol/L. We com-
pared the very ﬁrst capsaicin provocation with
the second provocation of the first year; the
interval between these was about 3 months.
The number of coughs after inhalation of
2 µmol/L capsaicin correlated significantly
between these two provocation events
(r = 0.78; p < 0.001) (Figure 3A). The SD
from the mean difference between the 17 pairs
of repeated measurements among the patients
was 24 coughs for the 2-µmol/L capsaicin
dose. The coefﬁcient of repeatability was thus
calculated to be 48 coughs (Figure 3B). 
To evaluate the patients’ sensory reactivity
in a longer perspective, we examined the
repeatability of the capsaicin inhalation test
using the same technique. We analyzed the
two appointments in which the largest num-
ber (n = 15) of the same participants attended:
the last provocation of the first year and the
provocation of the third year. The number of
coughs after inhalation of 2 µmol/L capsaicin
correlated significantly between these two
provocation occasions (r = 0.76; p < 0.001)
(Figure 4A). The SD from the mean differ-
ence between the 15 pairs of repeated meas-
urements among the patients was 21.5 coughs
for the 2-µmol/L capsaicin dose. The coeffi-
cient of repeatability was thus calculated to be
43 coughs (Figure 4B). 
Discussion
In this 5-year study, we followed 17 patients
with previously medically unexplained airway
symptoms induced by chemicals and scents.
These symptoms are often misdiagnosed as
asthma or allergy, but they can be recognized
using a capsaicin inhalation cough test
(Johansson et al. 2002; Millqvist et al. 1998).
According to this test, the majority of the
patients in the present study (15 of 17) could
be diagnosed with SHR. None of the patients
recovered from their symptoms, and none
developed asthma, chronic obstructive pul-
monary disease, or any other known lung 
disease. After 5 years, brief exposure to sub-
stances such as perfume, colored paints, or
cigarette smoke could still evoke symptoms,
which had a long-term negative impact on the
daily life of the patients. The patients
reported long-lasting impairment in five of
the seven activities in part II of the NHP
(paid employment, housework, social life,
hobbies, and holidays) compared with a
population sample. They also reported signiﬁ-
cantly higher scores (more difficulties) for
social isolation in part I of the NHP. 
None of the patients in the present study
demonstrated any serious adverse reaction or
bronchoconstriction after the capsaicin
Ternesten-Hasséus et al.
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Figure 2. Box plot presentation of cough response after inhalation of two concentrations of capsaicin,
0.4 µmol/L and 2 µmol/L, on ﬁve separate occasions over 5 years. Year 1 n:04, fourth provocation in the ﬁrst
year. The horizontal line in the center of each box is the median; the top and bottom of the box represent
the 25th and 75th percentiles; and whiskers indicate the 10th and 90th percentiles. Circles indicate individ-






















Year 1 n:04 Year 2 Year 3 Year 4 Year 5 Year 1 n:04 Year 2 Year 3 Year 4 Year 5
Figure 3. (A) Repeatability of the number of coughs provoked by the inhalation of 2 µmol/L capsaicin in
17 patients on the ﬁrst (n:01) and second (n:02) occasions of the ﬁrst year (r = 0.78; p < 0.001). (B) Difference
between the measurements on the ﬁrst and second provocation occasions of the ﬁrst year against their
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Figure 4. (A) Repeatability of the number of coughs provoked by the inhalation of 2 µmol/L capsaicin in
15 patients on the last provocation of the ﬁrst year and on the provocation of the third year (r = 0.76; p < 0.001).
(B) Difference between the measurements on the last capsaicin provocation of the ﬁrst year and on the provo-
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A Binhalation test. In a recent review, Dicpinigaitis
and Alva (2005) concluded capsaicin inhala-
tion to be a safe research tool, with no serious
adverse reactions reported over the past two
decades. In two other studies with long-term
occupational exposure to capsaicin, no
demonstrable change in pulmonary function
was seen (Blanc et al. 1991; Lankatilake and
Uragoda 1993). Inhalation of three incre-
ments of capsaicin contains a total of
0.00377 g capsaicin, if the subject is able to
inhale all three concentrations. This can be
compared to a meal containing 100 g of fresh
chili peppers, which would contain 0.1–1 g
pure capsaicin. In some countries, consump-
tion can be as high as approximately 3 g pure
capsaicin per day (Govindarajan 1986). From
this perspective, it seems unlikely that the
capsaicin inhalation test could pose any risk
to the patients.
Capsaicin-induced cough can, to a certain
extent, be voluntarily suppressed or enhanced
(Hutchings et al. 1993). Some individuals can
avoid coughing when inhaling capsaicin, but
the cough reflex becomes irresistible with
increasing concentrations. In previous studies,
inhalation of capsaicin induced a dose-depen-
dent and reproducible cough in patients with
SHR and healthy controls, when the capsaicin
provocations were performed in a double-
blind randomized fashion (Millqvist 2000;
Ternesten-Hasseus et al. 2002a, 2006). With
regard to the good long-term reproducibility,
it seems unlikely that the patients could have
intentionally influenced the outcome of the
cough provocations. Although we found some
individual changes in capsaicin cough sensitiv-
ity, the sensory reactivity among the patients
was increased and long-standing. 
Medically unexplained physical symptoms
are common in clinical care and within the
general population; examples include chronic
fatigue syndrome, fibromyalgia, MCS, idio-
pathic environmental intolerances, somato-
form disorders, and “Gulf War syndrome.”
These symptoms are associated with extensive
morbidity and have a significant impact on
everyday functions (Baldwin et al. 1997; Black
et al. 1999; Kipen et al. 1995; Kreutzer et al.
1999; Meggs et al. 1996). The association of
these symptoms and syndromes with environ-
mental exposure is often sharply debated, as is
the distinction between the various syn-
dromes themselves (Kipen and Fiedler 2002;
Richardson and Engel 2004; Wiesmuller
et al. 2003). However, in spite of the uncer-
tainties in the evaluation of environmental
syndromes, physicians have a duty to deal
with the symptoms of those affected. 
In conclusion, airway symptoms induced
by chemicals and scents can be regarded as a
chronic condition and may represent an entity
of chronic diseases, with persistent symptoms,
a reduced HRQL, and unchanged long-lasting
sensory hyperreactivity. The repeatability for
the capsaicin inhalation test is good in a short-
term and long-term perspective. Although the
capsaicin inhalation test was valuable for diag-
nosing these patients, the cause of their symp-
toms remains obscure, and there is currently
no effective treatment; this emphasizes the
need for future pathophysiologic research.
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